Comparison of prognostic value of red cell distribution width and NT-proBNP for short-term clinical outcomes in acute heart failure patients

International Heart Journal

Volumn 55, Issue 1, 2014, Pages 58-64

  He, Wenyan ^a   Jia, Jun ^a   Chen, Jia ^a   Qin, Shu ^a   Tao, Hongmei ^a   Kong, Qianran ^a   Xue, Qiu ^a   Zhang, Dongying ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Marker; Prognosis

Indexed keywords

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHINA; ERYTHROCYTE INDICES; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84893619856     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.13-172     Document Type: Article

References (35)

1. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112: 3958-68.
2. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: the case of heart failure. Arch Intern Med 1999; 159: 1690-1700. (Review)
3. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416.
4. Park HS, Kim H, Sohn JH, et al. Combination of uric acid and NT-ProBNP: a more useful prognostic marker for short-term clinical outcomes in patients with acute heart failure. Korean J Intern Med 2010; 25: 253-9.
5. van Kimmenade RR, Mohammed AA, Uthamalingam S, van de Meer P, Felker GM, Januzzi JL Jr. Red blood cell distribution width and 1-year mortality in acute heart failure. Eur J Heart Fail 2010; 12: 129-36.
6. Förhécz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohászka Z, Jánoskuti L. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, infl ammation, renal function, and nutritional state. Am Heart J 2009; 158: 659-66.
7. Hong N, Oh J, Kang SM, et al. Red blood cell distribution width predicts early mortality in patients with acute dyspnea. Clin Chim Acta 2012; 413: 992-7.
8. Ani C, Ovbiagele B. Elevated red blood cell distribution width predicts mortality in persons with known stroke. J Neurol Sci 2009; 277: 103-8.
9. Dabbah S, Hammerman H, Markiewicz W, Aronson D. Relation between red cell distribution width and clinical outcomes after acute myocardial infarction. Am J Cardiol 2010; 105: 312-7.
10. Rhodes CJ, Wharton J, Howard LS, Gibbs JS, Wilkins MR. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary hypertension. Heart 2011; 97: 1054-60.
11. Ozkalemkas F, Ali R, Ozkocaman V, et al. The bone marrow aspirate and biopsy in the diagnosis of unsuspected nonhematologic malignancy: a clinical study of 19 cases. BMC Cancer 2005; 5: 144.
12. Shehata HA, Ali MM, Evans-Jones JC, Upton GJ, Manyonda IT. Red cell distribution width (RDW) changes in pregnancy. Int J Gynaecol Obstet 1998; 62: 43-6.
13. Cakal B, Akoz AG, Ustundag Y, Yalinkilic M, Ulker A, Ankarali H. Red cell distribution width for assessment of activity of infl ammatory bowel disease. Dig Dis Sci 2009; 54: 842-7.
14. Pascual-Figal DA, Bonaque JC, Redondo B, et al. Red blood cell distribution width predicts long-term outcome regardless of anaemia status in acute heart failure patients. Eur J Heart Fail 2009; 11: 840-6.
15. Makhoul BF, Khourieh A, Kaplan M, Bahouth F, Aronson D, Azzam ZS. Relation between changes in red cell distribution width and clinical outcomes in acute decompensated heart failure. Int J Cardiol 2012; 167: 1412-6.
16. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006; 113: 2454-61. (Review)
17. Felker GM, Adams Jr KF, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004; 44: 959-66. (Review)
18. Kalantar-Zadeh K, Anker SD, Horwich TB, Fonarow GC. Nutritional and anti-infl ammatory interventions in chronic heart failure. Am J Cardiol 2008; 101: 89E-103E. (Review)
19. Torre-Amione G, Anker SD, Bourge RC, et al. Results of a nonspecifi c immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 2008; 371: 228-36.
20. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-23. (Review)
21. Ershler WB, Sheng S, McKelvey J, et al. Serum erythropoietin and aging: a longitudinal analysis. J Am Geriatr Soc 2005; 53: 1360-5.
22. Ferrucci L, Guralnik JM, Woodman RC, et al. Proinfl ammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 2005; 118: 1288.
23. Emans ME, van der Putten K, van Rooijen KL, et al. Determinants of red cell distribution width (RDW) in cardiorenal patients: RDW is not related to erythropoietin resistance. J Card Fail 2011; 17: 626-33.
24. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-68. (Review)
25. Maisel A, Mueller C, Adams K, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-39. (Review)
26. Goetze JP, Gore A, Møller CH, Steinbrüchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004; 18: 1928-30.
27. Sakata Y, Yamamoto K, Masuyama T, et al. Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. J Hypertens 2001; 19: 1905-12.
28. Feng J, Schaus BJ, Fallavollita JA, Lee TC, Canty JM Jr. Preload induces troponin I degradation independently of myocardial ischemia. Circulation 2001; 103: 2035-7.
29. Chen CY, Yoshida A, Asakura M, et al. Serum blood urea nitrogen and plasma brain natriuretic peptide and low diastolic blood pressure predict cardiovascular morbidity and mortality following discharge in acute decompensated heart failure patients. Circ J 2012; 76: 2372-9.
30. Filippatos G, Rossi J, Lloyd-Jones DM, et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail 2007; 13: 360-4.
31. Kazory A. Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am J Cardiol 2010; 106: 694-700. (Review)
32. Miura M, Sakata Y, Nochioka K, et al. Prognostic impact of blood urea nitrogen changes during hospitalization in patients with acute heart failure syndrome. Circ J 2013; 77: 1221-8.
33. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112: 3958-68.
34. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217-26.
35. Basu S. The neglected role of blood pressure in acute heart failure syndrome. Heart 2012; 98: 91.